株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

糖尿病性腎障害 : パイプライン分析

Diabetic Nephropathy - Pipeline Review, H2 2017

発行 Global Markets Direct 商品コード 192557
出版日 ページ情報 英文 214 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.19円で換算しております。
Back to Top
糖尿病性腎障害 : パイプライン分析 Diabetic Nephropathy - Pipeline Review, H2 2017
出版日: 2017年08月22日 ページ情報: 英文 214 Pages
概要

糖尿病性腎障害とは、糖尿病による発症する腎臓の損傷を指します。疾患の主な特徴としてアルブミン尿や、糸球体濾過率の低下、高血圧などがあります。疾病素質には、肥満症や高血圧、高脂血・高糖血、喫煙などがあります。薬物両用や食生活改善などで症状が緩和する可能性があります。

当レポートでは、世界各国での糖尿病性腎障害治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

糖尿病性腎障害の概要

治療薬の開発

  • 糖尿病性腎障害向けパイプライン製品:概要
  • 糖尿病性腎障害向けパイプライン製品:比較分析

各企業で開発中の糖尿病性腎障害治療薬

大学/研究機関で研究中の糖尿病性腎障害治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

糖尿病性腎障害治療薬:開発中の製品の一覧(企業別)

糖尿病性腎障害治療薬:研究中の製品の一覧(大学/研究機関別)

糖尿病性腎障害治療薬の開発に従事している企業

  • AbbVie Inc.
  • Antisense Therapeutics Limited
  • Arena Pharmaceuticals, Inc.
  • アステラス製薬
  • AstraZeneca Plc
  • Bayer AG
  • BiOrion Technologies B.V.
  • Boehringer Ingelheim GmbH
  • Cellmid Limited
  • ChemoCentryx, Inc.
  • Concert Pharmaceuticals, Inc.
  • CSL Limited
  • 第一三共
  • Dimerix Bioscience Pty Ltd
  • Dong Wha Pharma Co., Ltd.
  • Dynamis Therapeutics, Inc.
  • Eli Lilly and Company
  • Galectin Therapeutics, Inc.
  • GenKyoTex S.A.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline Plc
  • Glucox Biotech AB
  • GNI Group Ltd.
  • Islet Sciences, Inc.
  • Jenrin Discovery, Inc.
  • Johnson & Johnson
  • Mallinckrodt Plc
  • Mesoblast Limited
  • 田辺三菱製薬
  • MorphoSys AG
  • NephroGenex, Inc.
  • Noxxon Pharma AG
  • Omeros Corporation
  • 大塚ホールディングス
  • Pfizer Inc.
  • PhytoHealth Corporation
  • ProMetic Life Sciences Inc.
  • Serodus ASA
  • Shire Plc
  • 武田薬品工業
  • Theravance Biopharma, Inc.
  • Tobira Therapeutics, Inc.
  • Vascular Pharmaceuticals, Inc.
  • Vicore Pharma AB
  • XOMA Corporation

糖尿病性腎障害:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • 11-RVIVIT
    • 製品概要
    • 機能メカニズム
    • 研究開発(R&D)の進展状況
  • A-717
  • 癌用ヘパラナーゼ阻害小分子
  • APD-371
  • APX-115
  • ASP-8232
  • ATL-1103
  • 塩酸アトラセンタン
  • バリシチニブ
  • BI-703704
  • 糖尿病性腎障害向け生物製剤
  • BOT-191
  • C-21
  • カナグリフロジン
  • CCX-140 1
  • cenicriviroc mesylate
  • コルチコトロピン
  • CS-3150
  • CSL-346
  • CTP-499
  • Cyndacel-M
  • DMX-250
  • 糖尿病性心筋症・代謝性疾患向け Nrf2 活性化薬
  • DT-23552
  • DW-1029M
  • DYN-12
  • emapticap pegol
  • finerenone
  • gevokizumab
  • GKT-136901
  • GKT-831
  • GRMD-02
  • GW-610742
  • JD-5037
  • JNJ-39933673
  • リウマチ性関節炎・糖尿病合併症向け MASP-2阻害モノクローナル抗体
  • 癌・炎症性疾患・腎臓病向けミッドカイン阻害モノクローナル抗体
  • MOR-107
  • MPC-300IV
  • MT-3995
  • Nephrilin
  • oxypurinol
  • PBI-4050
  • PBI-4547
  • PF-00489791
  • PHN-033
  • pirfenidone
  • probucol
  • ピリドキサミン二塩化水素化物
  • selonsertib
  • SER-150
  • SHP-627
  • 糖尿病性腎障害向けNOX-4阻害用小分子
  • 糖尿病性腎障害向け小分子
  • 眼科学・心血管・中枢神経系・代謝性疾患向け小分子
  • 転移性癌・糖尿病性腎障害向けヘパラナーゼ阻害小分子
  • SP-20202
  • TAK-272
  • TAK-648
  • TBE-31
  • TD-0714
  • VPI-2690B
  • VS-105
  • XRX-108
  • XRX-221

糖尿病性腎障害治療薬:パイプライン製品の最新動向

糖尿病性腎障害治療薬:開発が休止状態の製品

糖尿病性腎障害治療薬:開発が中止された製品

糖尿病性腎障害関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9648IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Nephropathy - Pipeline Review, H2 2017, provides an overview of the Diabetic Nephropathy (Metabolic Disorders) pipeline landscape.

Diabetic nephropathy is the damage to the kidney occurring due to diabetes. It is characterized by albuminuria, reduction in glomerular filtration rate and high blood pressure. Risk factors include obesity, hypertension, high lipid and sugar levels and smoking. This condition is managed by medication and dietary modification.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Nephropathy - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Diabetic Nephropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Nephropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Nephropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 14, 10, 1, 32, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 3 molecules, respectively.

Diabetic Nephropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Diabetic Nephropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Diabetic Nephropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Diabetic Nephropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Nephropathy (Metabolic Disorders)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Diabetic Nephropathy (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Diabetic Nephropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Diabetic Nephropathy - Overview
    • Diabetic Nephropathy - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Diabetic Nephropathy - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Diabetic Nephropathy - Companies Involved in Therapeutics Development
    • AbbVie Inc
    • Allergan Plc
    • Antisense Therapeutics Ltd
    • Aptevo Therapeutics Inc
    • Araim Pharmaceuticals Inc
    • Arena Pharmaceuticals Inc
    • Astellas Pharma Inc
    • AstraZeneca Plc
    • Bayer AG
    • BLR Bio LLC
    • Boehringer Ingelheim GmbH
    • Cellmid Ltd
    • ChemoCentryx Inc
    • CSL Ltd
    • Daiichi Sankyo Company Ltd
    • DiaMedica Therapeutics Inc
    • Dynamis Therapeutics Inc
    • Galectin Therapeutics Inc
    • GenKyoTex SA
    • Gilead Sciences Inc
    • GNI Group Ltd
    • Islet Sciences Inc
    • Johnson & Johnson
    • MediPost Co Ltd
    • Mesoblast Ltd
    • Mitsubishi Tanabe Pharma Corp
    • MorphoSys AG
    • Noxxon Pharma AG
    • Omeros Corp
    • Paranta Biosciences Ltd
    • PhiloGene Inc
    • PhytoHealth Corp
    • ProMetic Life Sciences Inc
    • Redx Pharma Plc
    • Sarfez Pharmaceuticals Inc
    • Serodus ASA
    • Teijin Pharma Ltd
    • Theravance Biopharma Inc
    • Twoxar Inc
    • Vascular Pharmaceuticals Inc
    • Vicore Pharma AB
    • XORTX Pharma Corp
  • Diabetic Nephropathy - Drug Profiles
    • 11-RVIVIT - Drug Profile
    • A-717 - Drug Profile
    • Antibodies to Inhibit Heparanase for Alopecia, Colitis, Diabetic Nephropathy, Transplantation and Oncology - Drug Profile
    • apararenone - Drug Profile
    • APD-371 - Drug Profile
    • APX-115 - Drug Profile
    • ASP-8232 - Drug Profile
    • atesidorsen sodium - Drug Profile
    • atrasentan hydrochloride - Drug Profile
    • BI-685509 - Drug Profile
    • BI-690517 - Drug Profile
    • BI-703704 - Drug Profile
    • BLR-200 - Drug Profile
    • C-21 - Drug Profile
    • canagliflozin - Drug Profile
    • CCX-140 - Drug Profile
    • Cell Therapy for Chronic Kidney Disease and Metabolic Disorders - Drug Profile
    • cenicriviroc mesylate - Drug Profile
    • cibinetide - Drug Profile
    • CSL-346 - Drug Profile
    • Cyndacel-M - Drug Profile
    • DM-199 - Drug Profile
    • DM-399 - Drug Profile
    • Drugs for Diabetic Nephropathy - Drug Profile
    • DT-23552 - Drug Profile
    • DYN-12 - Drug Profile
    • emapticap pegol - Drug Profile
    • esaxerenone - Drug Profile
    • finerenone - Drug Profile
    • FM-1302 - Drug Profile
    • GKT-136901 - Drug Profile
    • GKT-831 - Drug Profile
    • GLY-230 - Drug Profile
    • GRMD-02 - Drug Profile
    • GS-444217 - Drug Profile
    • IL-233 - Drug Profile
    • IP-9 - Drug Profile
    • JD-5037 - Drug Profile
    • JNJ-39933673 - Drug Profile
    • MG-132 - Drug Profile
    • Monoclonal Antibodies to Inhibit MASP-2 for Diabetic Complications and Rheumatoid Arthritis - Drug Profile
    • MOR-107 - Drug Profile
    • MPC-300IV - Drug Profile
    • Orbcel-M - Drug Profile
    • PBI-4050 - Drug Profile
    • PBI-4425 - Drug Profile
    • PBI-4547 - Drug Profile
    • PHN-033 - Drug Profile
    • pirfenidone - Drug Profile
    • Recombinant Protein for Diabetic Nephropathy - Drug Profile
    • Recombinant Protein to Antagonize VEGFR-2 for Diabetic Nephropathy and Oncology - Drug Profile
    • REDX-06109 - Drug Profile
    • SCO-272 - Drug Profile
    • SER-150 - Drug Profile
    • Small Molecules for Diabetic Nephropathy - Drug Profile
    • Small Molecules to Inhibit AOC3 for Diabetic Nephropathy - Drug Profile
    • Small Molecules to Inhibit Heparanase for Metastatic Cancer and Diabetic Nephropathy - Drug Profile
    • Small Molecules to Inhibit Rho Kinase for Hypertension and Diabetic Nephropathy - Drug Profile
    • SP-20202 - Drug Profile
    • Stem Cell Therapy for Diabetic Nephropathy and Autoimmune Disorders - Drug Profile
    • TBE-31 - Drug Profile
    • TD-0714 - Drug Profile
    • TD-1439 - Drug Profile
    • TMX-049 - Drug Profile
    • TNFR x TWEAKR - Drug Profile
    • VAR-400 - Drug Profile
    • VPI-2690B - Drug Profile
    • VS-105 - Drug Profile
    • Wnt-001 - Drug Profile
    • XRX-108 - Drug Profile
    • XRX-221 - Drug Profile
  • Diabetic Nephropathy - Dormant Projects
  • Diabetic Nephropathy - Discontinued Products
  • Diabetic Nephropathy - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Diabetic Nephropathy, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Diabetic Nephropathy - Pipeline by AbbVie Inc, H2 2017
  • Diabetic Nephropathy - Pipeline by Allergan Plc, H2 2017
  • Diabetic Nephropathy - Pipeline by Antisense Therapeutics Ltd, H2 2017
  • Diabetic Nephropathy - Pipeline by Aptevo Therapeutics Inc, H2 2017
  • Diabetic Nephropathy - Pipeline by Araim Pharmaceuticals Inc, H2 2017
  • Diabetic Nephropathy - Pipeline by Arena Pharmaceuticals Inc, H2 2017
  • Diabetic Nephropathy - Pipeline by Astellas Pharma Inc, H2 2017
  • Diabetic Nephropathy - Pipeline by AstraZeneca Plc, H2 2017
  • Diabetic Nephropathy - Pipeline by Bayer AG, H2 2017
  • Diabetic Nephropathy - Pipeline by BLR Bio LLC, H2 2017
  • Diabetic Nephropathy - Pipeline by Boehringer Ingelheim GmbH, H2 2017
  • Diabetic Nephropathy - Pipeline by Cellmid Ltd, H2 2017
  • Diabetic Nephropathy - Pipeline by ChemoCentryx Inc, H2 2017
  • Diabetic Nephropathy - Pipeline by CSL Ltd, H2 2017
  • Diabetic Nephropathy - Pipeline by Daiichi Sankyo Company Ltd, H2 2017
  • Diabetic Nephropathy - Pipeline by DiaMedica Therapeutics Inc, H2 2017
  • Diabetic Nephropathy - Pipeline by Dynamis Therapeutics Inc, H2 2017
  • Diabetic Nephropathy - Pipeline by Galectin Therapeutics Inc, H2 2017
  • Diabetic Nephropathy - Pipeline by GenKyoTex SA, H2 2017
  • Diabetic Nephropathy - Pipeline by Gilead Sciences Inc, H2 2017
  • Diabetic Nephropathy - Pipeline by GNI Group Ltd, H2 2017
  • Diabetic Nephropathy - Pipeline by Islet Sciences Inc, H2 2017
  • Diabetic Nephropathy - Pipeline by Johnson & Johnson, H2 2017
  • Diabetic Nephropathy - Pipeline by MediPost Co Ltd, H2 2017
  • Diabetic Nephropathy - Pipeline by Mesoblast Ltd, H2 2017
  • Diabetic Nephropathy - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2017
  • Diabetic Nephropathy - Pipeline by MorphoSys AG, H2 2017
  • Diabetic Nephropathy - Pipeline by Noxxon Pharma AG, H2 2017
  • Diabetic Nephropathy - Pipeline by Omeros Corp, H2 2017
  • Diabetic Nephropathy - Pipeline by Paranta Biosciences Ltd, H2 2017
  • Diabetic Nephropathy - Pipeline by PhiloGene Inc, H2 2017
  • Diabetic Nephropathy - Pipeline by PhytoHealth Corp, H2 2017
  • Diabetic Nephropathy - Pipeline by ProMetic Life Sciences Inc, H2 2017
  • Diabetic Nephropathy - Pipeline by Redx Pharma Plc, H2 2017
  • Diabetic Nephropathy - Pipeline by Sarfez Pharmaceuticals Inc, H2 2017
  • Diabetic Nephropathy - Pipeline by Serodus ASA, H2 2017
  • Diabetic Nephropathy - Pipeline by Teijin Pharma Ltd, H2 2017
  • Diabetic Nephropathy - Pipeline by Theravance Biopharma Inc, H2 2017
  • Diabetic Nephropathy - Pipeline by Twoxar Inc, H2 2017
  • Diabetic Nephropathy - Pipeline by Vascular Pharmaceuticals Inc, H2 2017
  • Diabetic Nephropathy - Pipeline by Vicore Pharma AB, H2 2017
  • Diabetic Nephropathy - Pipeline by XORTX Pharma Corp, H2 2017
  • Diabetic Nephropathy - Dormant Projects, H2 2017
  • Diabetic Nephropathy - Dormant Projects, H2 2017 (Contd..1), H2 2017
  • Diabetic Nephropathy - Dormant Projects, H2 2017 (Contd..2), H2 2017
  • Diabetic Nephropathy - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Diabetic Nephropathy, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Top 10 Molecule Types, H2 2017
  • Number of Products by Stage and Top 10 Molecule Types, H2 2017
Back to Top